Friday, January 06, 2023 9:14:08 PM
Flipper,
I think that they will enter into some forms of partnerships over the next year. It has always been my opinion and hope that they will partner up with one or more BP’s in regard to a number of various cancer indications. I don’t think the first step will be a buy out, though it could come at a later time through the partnerships. I think LP will be willing to enter into partnerships with little to no equity in NWBO, but with exclusive rights in Mucidencel for certain types of cancer. This is a way for NWBO to maximize the value of Murcidencel and still be able to maximize the later price for the company. This also gives BP a way to acquire what they need, without having a mutiny among their shareholders for over paying for NWBO at this time. I would have expected this to happen prior to many of the future milestones with bonuses for each milestone achieve, but it could also happen after they achieve more milestones.
They cannot sit idle by, which is why they continue to move on with the company as they see prudent. The points you mention will also be important should they enter into partnerships, as they are necessary for the future. JMHO
I think that they will enter into some forms of partnerships over the next year. It has always been my opinion and hope that they will partner up with one or more BP’s in regard to a number of various cancer indications. I don’t think the first step will be a buy out, though it could come at a later time through the partnerships. I think LP will be willing to enter into partnerships with little to no equity in NWBO, but with exclusive rights in Mucidencel for certain types of cancer. This is a way for NWBO to maximize the value of Murcidencel and still be able to maximize the later price for the company. This also gives BP a way to acquire what they need, without having a mutiny among their shareholders for over paying for NWBO at this time. I would have expected this to happen prior to many of the future milestones with bonuses for each milestone achieve, but it could also happen after they achieve more milestones.
They cannot sit idle by, which is why they continue to move on with the company as they see prudent. The points you mention will also be important should they enter into partnerships, as they are necessary for the future. JMHO
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
